Abbott India's quarterly profit climbs 28% on strong demand

Abbott India

15/05/2025 15:09

May 15 (Reuters) - Drugmaker Abbott India ABOT.NS reported a 28% rise in fourth-quarter profit on Thursday, helped by strong demand for its gastrointestinal and anti-infective medications.

The company, known for its PediaSure nutrition drink, reported a profit of 3.67 billion rupees ($43 million) for the quarter ended March 31, up from 2.87 billion rupees a year ago.

Revenue from operations climbed 11.5% to 16.05 billion rupees.

For further highlights, click nFWN3RN30U.

KEY CONTEXT

Anti-diabetic, cardiovascular and gastrointestinal drugs, which form a major chunk of Abbott India's drugs portfolio, saw the highest demand during the quarter, Elara Capital said.

Moreover, strong demand for Rybelsus, the oral version of Novo Nordisk's NOVOb.CO blockbuster weight-loss drug semaglutide distributed by Abbott in India, also boosted sales, analysts said.

Peer JB Chem and Pharma also reported higher quarterly profit on strong demand for its gastrointestinal drugs.

PEER COMPARISON

Estimates (next 12 months)
Analysts' sentiment
RIC
PE
EV/EBITDA
Revenue growth (%)
Profit growth (%)
Mean rating*
# of analysts
Stock to price target**
Div yield (%)
Abbott India Ltd
ABOT.NS
40.87
32.03
7.38
12.64
Strong Buy
5
0.91
1.35
GlaxoSmithKline Pharmaceuticals Ltd
GLAX.NS
48.46
34.33
9.49
12.37
Buy
4
0.94
1.46
Torrent Pharmaceuticals Ltd
TORP.NS
42.87
25.10
13.07
31.20
Hold
24
0.92
0.99
J B Chemicals and Pharmaceuticals Ltd
JBCH.NS
31.47
19.86
12.65
20.58
Buy
11
0.77
0.76

 * Mean of analysts' ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell
 ** Ratio of the stock's last close to analysts' mean price target; a ratio above 1 means the stock is trading above the PT

JANUARY TO MARCH STOCK PERFORMANCE

-- All data from LSEG

-- $1 = 85.4620 Indian rupees

JANUARY TO MARCH STOCK PERFORMANCE https://tmsnrt.rs/4j3u6Ow

 (Reporting by Kashish Tandon and Nandan Mandayam in Bengaluru; Editing by Shailesh Kuber)

 ((Kashish.Tandon@thomsonreuters.com))